The Food and Drug Administration has required a black box warning to be included on the drug Reglan (metoclopramide), and has ordered the implementation of a risk evaluation and mitigation strategy, or REMS, to ensure patients are provided with a medication guide that discusses this risk.
Manufactured by Baxter Healthcare Corporation and used to treat GER & GERD (Gastrointestinal Reflux & Gastrointestinal Reflux Disease), two studies have determined that 27 to 29 percent of long term users of Reglan come down with Tardive Dyskinesia.
Tardive dyskinesia is characterized by involuntary, repetitive movements of the extremities, or lip smacking, grimacing, tongue protrusion, rapid eye movements or blinking, puckering and pursing of the lips, or impaired movement of the fingers. These symptoms are rarely reversible and there is no known treatment. However, in some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
If you have been injured or hurt using Reglan or other Metoclopramide drugs, you may be entitled to compensation. Please contact one of our pharmaceutical drug lawyers at Carr & Carr Attorneys. The lawyers at Carr & Carr Attorneys have represented thousands of injured individuals for over 35 years in Oklahoma, Arkansas and across the rest of the country.
Posted by Michael
Related posts:
- Are You Suffering These Side Effects From the Use of Reglan?
- Digitek Digoxin Recall Issued
- Major Recall of Umbrella Strollers
- Warnings Announced for Prescriptions Containing Acetaminophen
- Psoriasis Drug Recalled Due to Risk of Neurological Disease
Tags: metoclopramide, reglan, tardive
